The latest update on Wednesday morning shows ResMed shares down by 0.02%, trading at $246.16. At this price, Farrell's 11,442 ...

Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

The incoming AdvaMed chair talked about updates to Resmed’s products and how the company is handling competitive dynamics and ...

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ). ResMed Inc has reported ...

ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.

ResMed Inc. ( NYSE:RMD ) shareholders might be concerned after seeing the share price drop 15% in the last quarter.

Shares of ResMed Inc. slipped 3.03% to $244.46 Friday, on what proved to be an all-around dismal trading session for the ...

Tariffs on medical devices would push up prices and disrupt research and development efforts at the expense of US patients, the Australian giants argue.

For the past 18 months, ResMed Chief Executive Mick Farrell has been publicly outspoken in urging that medical devices get priority access to semiconductors amid global chip shortages coming out of ...

55% of HME respondents say mask selection is the biggest challenge during remote CPAP setups in a recent survey SAN DIEGO--(BUSINESS WIRE)--ResMed (NYSE: RMD, ASX: RMD) has launched ResMed ...

Nearlyhalf of workforce has missed work at least once due to sleep-related fatigue, according to ResMed’s Global Sleep Study ...

We believe that ResMed (NYSE: RMD), a medical equipment company, currently appears to be an attractive pick over Ciena stock (NYSE: CIEN), a telecommunications networking equipment and software ...